Drug intelligence / Profile preview

CB101 (Cascade Biotechnology)

Development stage: Preclinical
Lead developer: Cascade Biotechnology
Modality: Recombinant Proteins and Enzymes

Overview

CB101 is Cascade Biotechnology's investigational complement-directed program for diabetic nephropathy and lupus nephritis. The company lists CB101 in development-scale-up for IND-enabling GLP studies and describes its broader platform as stabilized C3, a complement-depleting protein approach intended to reduce pathogenic complement activity. The exact molecular construct, formulation, route of administration, and specific binding interactions for CB101 have not been publicly disclosed. ([cascadebiotechnology.com](https://www.cascadebiotechnology.com/pipeline-1))

Targets

Beyond the preview

Go deeper on CB101 (Cascade Biotechnology).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB101 (Cascade Biotechnology).

Explore the full profile